SEC Company Response from Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Nov 12, 2013
Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: Nov. 12, 2013 · CIK: 0000908259 · Accession: 0001193125-13-438709
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-191531
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Jeffrey P. Riedler, Assistant Director Re: OXiGENE, Inc. Registration Statement on Form S-3 Filed October 2, 2013 File No. 333-191531
Dear Mr. Riedler:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of OXiGENE, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Wednesday, November 13, 2013 at 4:30 p.m., or as soon as practicable thereafter.
In connection with the foregoing request, the Company acknowledges the following:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Megan N. Gates of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 348-4443 with any comments or questions regarding the Registration Statement.
Sincerely,
/s/ Peter J. Langecker
Show Raw Text
CORRESP 1 filename1.htm Correspondence OXiGENE, Inc. 701 Gateway Blvd., Suite 210 South San Francisco, CA 94080 November 12, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: OXiGENE, Inc. Registration Statement on Form S-3 Filed October 2, 2013 File No. 333-191531 Dear Mr. Riedler: With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of OXiGENE, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Wednesday, November 13, 2013 at 4:30 p.m., or as soon as practicable thereafter. In connection with the foregoing request, the Company acknowledges the following: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Megan N. Gates of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 348-4443 with any comments or questions regarding the Registration Statement. Sincerely, /s/ Peter J. Langecker Peter J. Langecker Chief Executive Officer OXiGENE, Inc.